Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | XBP1 | P17861 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27538352 | 0.72 | — | — | |
| SCHEMBL5988030 | 0.72 | CYP2A6 (0.33) | KDM4EALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL14986261 | 0.72 | — | — | |
| Hydrochloric Acid SCHEMBL27504580 | 0.71 | HSD17B10 (0.36) | KDM4EALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL12763605 | 0.69 | KDM4E (0.33) | KDM4EALDH1A1SMN1; SMN2HPGDUSP2 | |
| SCHEMBL22833105 | 0.68 | — | — | |
| SCHEMBL12917936 | 0.68 | — | — | |
| SCHEMBL22832657 | 0.68 | — | — | |
| SCHEMBL28736525 | 0.68 | DAO (0.45) | MGLLALOX15GAA | |
| SCHEMBL1468406 | 0.68 | KDM4E (0.34) | KDM4EALDH1A1SMN1; SMN2HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11712438-B2 | Phenyl derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-08-01 | — | — | US | disclosed |
| US-20220363673-A1 | 5-(Thiophen-2-YL)-1 H-Tetrazole Derivative as BCKDK Inhibitors Useful for Treating Various Diseases | PFIZER INC. (US) | 2022-11-17 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-3990452-A1 | 5-(THIOPHEN-2-YL)-1H-TETRAZOLE DERIVATIVES AS BCKDK INHIBITORS USEFUL FOR TREATING VARIOUS DISEASES | Pfizer Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| EP-2710018-B1 | MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | FUNDACION CENTRO NAC DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) | 2021-12-29 | — | — | EP | disclosed |
| EP-2710018-B1 | MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | FUNDACION CENTRO NAC DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) | 2021-12-29 | — | — | EP | disclosed |
| EP-3625222-B1 | PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-07-21 | — | — | EP | disclosed |
| WO-2020261144-A1 | 5-(THIOPHEN-2-YL)-1H-TETRAZOLE DERIVATIVES AS BCKDK INHIBITORS USEFUL FOR TREATING VARIOUS DISEASES | PFIZER INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| US-20200179383-A1 | PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2020-06-11 | — | — | US | disclosed |
| EP-3625222-A1 | PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2020-03-25 | — | — | EP | disclosed |
| EP-2726479-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co KG (DE) | 2014-05-07 | — | — | EP | disclosed |
| EP-2710018-A2 | NEW COMPOUNDS | Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) | 2014-03-26 | — | — | EP | disclosed |
| WO-2013000994-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBOTT GMBH & CO. KG (DE) | 2013-01-03 | — | — | WO | disclosed |
| US-20130005705-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBOTT LABORATORIES (US) | 2013-01-03 | — | — | US | disclosed |
| WO-2012156756-A2 | NEW COMPOUNDS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012156756-A2 | NEW COMPOUNDS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2012-11-22 | — | — | WO | disclosed |
| WO-2009049028-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USE AS JANUS KINASE MODULATORS | TARGEGEN INC. (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009049028-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USE AS JANUS KINASE MODULATORS | TARGEGEN INC. (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009026345-A1 | THIAZOLIDINONE COMPOUNDS, AND METHODS OF MAKING AND USING SAME | TARGEGEN INC. (US) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009026345-A1 | THIAZOLIDINONE COMPOUNDS, AND METHODS OF MAKING AND USING SAME | TARGEGEN INC. (US) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11712438-B2 | Phenyl derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | KDM4E 842/4885ALDH1A1 575/4885SMN1; SMN2 4692/4885 |
| US-20220363673-A1 | 5-(Thiophen-2-YL)-1 H-Tetrazole Derivative as BCKDK Inhibitors Useful for Treating Various Diseases | BCKDK, PDK4, PFKL | KDM4E 1384/4885ALDH1A1 458/4885SMN1; SMN2 4188/4885 |
| US-20200179383-A1 | PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS | PTGER1, PTGER4, PTGER2 | KDM4E 791/4885ALDH1A1 527/4885SMN1; SMN2 4733/4885 |
| US-20130005705-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE2A, PDE4A, PDE5A | KDM4E 655/4885ALDH1A1 279/4885SMN1; SMN2 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.